NCT04370730Recruiting
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 25 Mar 2020
- Start date
- 2 Jun 2021
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Schizophrenia
- NCT number
- NCT04370730
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 2 Jun 2021 to the primary completion date, 1 Oct 2026
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse.
- Diagnosis of bipolar disorder.
Other
- Moderate or severe intellectual deficiency (IQ \< 50).
- Patients who are under legal guardianship.
- For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.
Who the study is looking for
- Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years.
- Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic.
- DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features.
- Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits.
- Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional).
- Has health insurance coverage from Social Security (France) (not AME coverage).
- Parents : no specific criteria.
- Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family.
- Written informed consent for the genetic part of the study signed by any participating parents and siblings.
- Has health insurance coverage from Social Security (France) (not AME coverage).
Age in the registry: 7 years to 20 years · Sex: All · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondation Vallée, Gentilly Coordinator of this site? Confirm its status | Gentilly | France | Not yet recruiting |
| CHRU de Lille Coordinator of this site? Confirm its status | Lille | France | Not yet recruiting |
| CHU de Nice Coordinator of this site? Confirm its status | Nice | France | Not yet recruiting |
| Pitié-Salpêtrière Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| CHU de Rouvray Coordinator of this site? Confirm its status | Rouen | France | Not yet recruiting |
| CHU de Rouen Coordinator of this site? Confirm its status | Rouen | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.